Pharmafile Logo

dabigatran

- PMLiVE

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

- PMLiVE

NICE and ABPI clash over access to medicines

Trade body says research shows medicines underused but NICE claims new figures 'higher than expected'

- PMLiVE

NICE stroke guidance boost for Boehringer’s Actilyse

Institute changes guidance on alteplase use

- PMLiVE

Patient access schemes likely to remain under VBP, says NICE

New and existing schemes expected to have place within UK’s new pricing environment

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

- PMLiVE

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links